Banyan Biomarkers Announces U.S. Patent for Neural Proteins as Biomarkers for Traumatic Brain Injury

ALACHUA, Fla. (PRWEB) September 4, 2008

Banyan Biomarkers also holds the exclusive license from the University of Florida for U.S. Patent No. 7,291,710 “Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cell damage.”

Gary Ascani, Chief Executive Officer of Banyan Biomarkers, Inc., commented, “Banyan continues to effectively build its intellectual property portfolio and broaden our applications for biomarkers as critical tools for assisting physicians in diagnosing and managing patients with traumatic brain injuries and other acute central nervous system injuries such as stroke.”

Approximately 1.9 million traumatic brain injuries are sustained annually. In a comparison provided by the Brain Injury Association of America, more traumatic brain injuries occur annually than the combined incidences of multiple sclerosis, spinal cord injuries, HIV/AIDS and breast cancer.

Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and facilitate the diagnosis and management of head injured patients. Banyan Biomarkers also uses the company’s proprietary biomarkers to provide testing services for the pharmaceutical industry in the evaluation of drug candidates for pre-clinical and clinical studies. To learn more about Banyan Biomarkers, Inc., visit www.banyanbio.com